Trial Profile
A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy Immune cell (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- Sponsors Immune Cell Therapy
- 04 Jan 2018 New trial record